• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Hospital Participation in ACOs Associated With Other Value-Based Program Improvement

Publication
Article
The American Journal of Managed CareJuly 2016
Volume 22
Issue 7

Analyzes whether hospital participation in accountable care organizations is associated with a hospital’s quality and cost improvement outcomes in other Medicare value-based payment programs.

Articles in this issue
Medical Record Privacy and State Health Reform After Gobeille v. Liberty Mutual Insurance Co.
Enhanced Risk Prediction Model for Emergency Department Use and Hospitalizations in Patients in a Primary Care Medical Home
Shared Medical Appointments: Balancing Efficiency With Patient Satisfaction and Outcomes
Insurance Coverage and Diabetes Quality Indicators Among Patients in NHANES
Choosing Wisely Campaign Builds Momentum
A Restricted Look at CRC Screening: Not Considering Annual Stool Testing as an Option
Impact of a Physician-Led Point of Care Medication Delivery System on Medication Adherence
Testing of a Tethered Personal Health Record Framework for Early End-of-Life Discussions
Hospital Participation in ACOs Associated With Other Value-Based Program Improvement
Economic and Clinical Impact of Routine Weekend Catheterization Services
Changes in Premiums of Cancelled Nongroup Plans Under the Affordable Care Act
Related Videos
Most employees are unprepared to shop for coverage on their own, underscoring the need for stronger decision tools and consumer protections.
Experts warn that ICHRAs could either stabilize or destabilize the individual market, depending on which workers employers shift into these plans.
Where patients live may shape outcomes in hypertrophic cardiomyopathy, with SDOH linked to higher risks of heart failure and arrhythmias.
Eleanor Perfetto, PhD
Tom Kim, chief medical officer, Sound Long-Term Care Management
Related Content
Socioeconomic and demographic factors were associated with variations in surgical outcomes among patients with upper extremity soft tissue sarcoma. | Image credit: @syahrir-adobestock.jpeg

Socioeconomic Factors Linked to Surgical Outcomes in Upper Extremity Soft Tissue Sarcoma

January 22nd 2026
Article

Socioeconomic and demographic factors influenced amputation and recurrence rates in upper extremity soft tissue sarcoma.

Read More

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

January 20th 2026
Podcast

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

AJMC research letter

Specialty and Operator Status Influence Electronic Health Record Use Variation

January 22nd 2026
Article

Operators demonstrated specialty-specific differences in electronic health record efficiency, timeliness, and after-hours use, highlighting how workflow and training shape documentation behaviors across medical disciplines.

Read More

2026 Health Care Predictions: AI, GLP-1s, MAHA, DEI: Sachin H. Jain, MD, MBA

2026 Health Care Predictions: AI, GLP-1s, MAHA, DEI: Sachin H. Jain, MD, MBA

January 1st 2026
Podcast

Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.

Listen

NYC’s largest nursing strike hits Day 5 as nurses push for safer staffing, fair benefits, and workplace protections. Hospitals continue negotiations. | Image credit: @Sansert_AdobeStock.jpeg

NYC Nurses Strike Enters Day 5 Amid Staffing, Safety, and Benefit Disputes

January 16th 2026
Article

New York City nurses continue their strike over staffing, safety, and benefits through negotiations on day 5 of the city’s largest nursing strike.

Read More

France has expanded early access to the dual immunotherapy botensilimab plus balstilimab for select ovarian cancers and soft tissue sarcomas. | Image credit: @Tamer_AdobeStock.jpeg

France Expands BOT–BAL Immunotherapy Access for Ovarian Cancer and Soft Tissue Sarcoma

January 16th 2026
Article

France approved botensilimab plus balstilimab for select ovarian cancers and soft tissue sarcomas, expanding early access to this dual immunotherapy.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.